ISOSORBIDE DINITRATE (ISDN) is widely employed in the management of patients with angina pectoris and is used with increasing frequency for impedance reduction in patients with left ventricular dysfunction. The usefulness of this drug was initially questioned because of extensive first-pass metabolism in the animal liver,1'2 but recent investigations have demonstrated that orally administered ISDN is readily detected in systemic blood,34 induces important hemodynamic effects,4 6 and is effective in the treatment of angina pectoris4' 7-10 and left ventricular dysfunction.5 6 A significant concern in the sustained use of organic nitrates is nitrate tolerance. Studies have shown rapid development of tolerance to the organic nitrates in animals and man and cross tolerance among various nitrates. [11] [12] [13] [14] [15] [16] Tolerance in humans was suggested in munitions workers when headaches and postural lightheadedness, which occurred with initial exposure, cleared within a few days of continued exposure. Loss of nitrate tolerance in these workers also occurred rapidly, as indicated by the return of the original symptoms after a weekend away from exposure to nitrate, the so-called Monday disease or Monday head.'7 Recent clinical studies have confirmed the early development of partial tolerance to the circulatory effects of ISDN and reduced antianginal efficacy after only 1 week of oral therapy. '5 16 The present investigation was designed to determine the rate of development of tolerance during initiation of therapy with oral ISDN and the rate of tolerance reversal after withdrawal of this drug.
Methods
Study population. Ten patients, nine men and one woman, ranging in age from 37 to 77 years (mean 56), with stable, exercise-induced angina pectoris were studied. Patients who had had previous exposure to ISDN or other oral or cutaneous nitrate preparations were not included. These patients had been taking nitroglycerin, but this was not used in the 24 hr before study and was not required in any patient during this period of investigation. Other exclusion characteristics included the presence of cardiomegaly, cardiac failure, cerebral vascular disease, hepatic disease, renal dysfunction, or the administration of fl-blocking agents or vasodilators. Patients were also excluded if they had a history of severe headaches or symptoms of postural hypotension after nitroglycerin administration.
Study design Day 1. After an overnight fast, control measurements were made of heart rate and blood pressure with patients in the supine and standing positions, and a 5 ml sample of venous THERAPY AND PREVENTION-PHARMACOLOGY blood was obtained. At approximately 9 A.M., 5 mg of sublingual ISDN was administered; the patients were instructed to indicate the time of dissolution of the tablet and were asked not to swallow their saliva. The heart rate and blood pressure measurements and venous blood samples were obtained at 2, 5.
10, 20, 30, 45, and 60 min and then at 30 min intervals for a total duration of 3 hr. At approximately 12 noon, 15 mg of ISDN was given orally and heart rate and blood pressure measurements were recorded hourly for 5 hr. Subsequent doses of ISDN were given at 6 P.M. and 12 midnight. Day 2. Fifteen milligrams of ISDN was administered orally at 6 A.M., 12 noon, 6 P.M., and 12 midnight.
Day 3. After an overnight fast, patients were studied at 9 A.M., i.e., 9 hr after the last dose of ISDN. The heart rate, blood pressure, and blood samples were taken before and after administration of 5 mg sublingual ISDN as on day 1. In addition, blood samples were collected at 60, 30, and 5 min before sublingual dosing. the plasma ISDN conrcentrations determined were then extrapolated by linear regression to correct for residual ISDN contributed by the last oral dose. At approximately 12 noon, 15 mg of ISDN was administered orally and heart rate and blood pressure were recorded at hourly intervals for 5 hr as on day 1 . Subsequently, an ISDN placebo was administered at 6 hr intervals, but the 6 A.M. dose was withheld on days 4 and 5.
Day 4. After an overnight fast, 9 hr after the last ISDN placebo and 21 hr after the last dose of ISDN, the patients were given 5 mg of sublingual ISDN and heart rate and blood pressure measurements were made over a 2 hr period, but no blood samples were obtained. If the systolic blood pressure decline approximated that seen on day 1, suggesting reversal of nitrate tolerance, the patient was studied again on the following day (day 5) with sublingual ISDN. On this occasion, in addition to measurements of heart rate and blood pressure, venous blood samples were drawn for measurement of ISDN concentration over a 3 hr period as on days 1 and 3. One patient did not show tolerance reversal until 48 hr after oral ISDN withdrawal (day 5), so the final study was carried out on day 6. The data from the patient studied on day 6 are included with the others and reported as day 5. This study was single blind in design. All studies were carried out by one individual, with blood pressure measurements made using one sphygmomanometer; single measurements were made from the same arm in each subject.
Venous blood (5 ml) was collected in tubes containing EDTA for determination of plasma ISDN concentrations. The total blood loss was 190 ml over a period of 5 days. The figure 1) STANDING. On day 3, after 48 hr of oral ISDN therapy and 9 hr after the last oral dose, the decline in SBP after the sublingual ISDN challenge was significantly less marked than that observed on day 1 (p < .025). On days 4 and 5, after institution of placebo ISDN therapy, the decline in SBP after sublingual ISDN challenge was similar to that observed on day 1 and significantly greater than that seen on day 3 (p < .025). The duration of the hypotensive effect after sublingual ISDN also differed during the study period. On day 3, SBP had returned to normal at the end of the 3 hr observation period, while the blood pressure had remained depressed at this time on days 1 and 5. No data are available beyond 2 hr on day 4 .
SUPINE. The changes in supine SBP were less marked than those seen in the standing position. However, a similar pattern of change occurred, with a decrease on day 3 that was significantly less than that observed on days 1, 4, and 5 (p < .02).
The duration of the hypotensive effect, on supine SBP was also different during the four study days. On day 3 the supine SBP had returned to normal after 3 hr, but this remained depressed at this time on days 1, 4, and 5.
DBP and heart rate (table 1). The changes in DBP followed a trend similar to that for changes in SBP, but there were no significant changes seen between the various study days in either the supine or standing positions. With the decline in SBP after sublingual ISDN, there were increases in heart rate, but there were no significant differences among the four study days.
Oral ISDN (table 2, figure 2 ). The changes in SBP after oral ISDN were similar during days 1 and 3, the only days when this was studied. It is important to point out that the SBP when the initial oral ISDN was administered on day 1 In addition, vasodilator therapy has been shown to activate the sympathetic nervous and renin-angiotensin systems. 29 30 The activation of these systems limits the hypotensive response, induces tachycardia, and may produce rebound changes after sudden withdrawal of vasodilator therapy. Therefore 
